• Longstanding experience in chromosomal analysis of leukemias (>10.000 cases)
  • In-depth analysis through molecular cytogenetic techniques (FISH0
  • Innovative development and application of a specially designed MLPA technique for the simultaneous detection of several clinically relevant microdeletions/microduplications associated with various hematological malignancies

InterGenetics has been actively involved for more than twenty years in the genetic investigation of tumors and particularly for leukemia. During these years, we have worked closely with almost all specialized hematology clinics in the country and with many established clinical hematologists, having addressed tens of thousands of individuals with hematological malignancies and having gained a unique experience in this field.

Trust in our quality and considerable expertise

InterGenetics was among the first to establish the technique of fluorescent in-situ hybridization (FISH), an indispensable technique for investigating chromosomal rearrangements such as microdeletions and microduplications, contributing to high-quality analysis and diagnosis, as well as to quantification of the genetic abnormalities associated with hematological diseases.

Our intensive development and expertise in the field has resulted in numerous original publications in international journals, while we have also developed internationally recognized innovative analytical methodologies (MLPA publication).

General information

Hematological malignancies are a type of cancer affecting the blood, bone marrow and lymph nodes. Since all three organs are intimately connected through the immune system, if one of the three is affected, there are usually repercussions in the others, e.g. lymphoma, a disease of the lymph nodes, is often spread to the bone marrow, which in turn affects the blood.

The genetic tests that follow are useful or even necessary in individuals with blood disorders for disease diagnosis and/or confirmation, e.g. in chronic and acute leukemias, for confirming remission or relapse after treatment, or for assessing the possible recurrence of the initial abnormality following bone marrow transplantation or other treatments.

Tests included in the group